Patents by Inventor Bassil I. Dahiyat

Bassil I. Dahiyat has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-glypican-3 antibody
    Patent number: 10118959
    Abstract: An anti-glypican-3 antibody comprising one or more amino acid substitutions introduced in the Fc region is disclosed. Preferably, in the anti-glypican-3 antibody, one or more of the amino acid residues at the positions 239, 298, 326, 330 and 332 in the Fc region are substituted with other amino acid residues. Since the Fc-modified anti-glypican-3 antibody of the invention exhibit enhanced ADCC activity, it is useful in treating cancers, such as hepatic cancer. Also disclosed are an anticancer agent comprising the anti-glypican-3 antibody of the invention and a pharmaceutically acceptable carrier, as well as a method of treating a patient with cancer comprising administering to the patient the anticancer agent of the invention.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: November 6, 2018
    Assignees: Chugai Seiyaku Kabushiki Kaisha, Xencor, Inc.
    Inventors: Gregory Alan Lazar, Bassil I. Dahiyat, Hisafumi Okabe, Masamichi Sugimoto, Shigeyuki Iijima, Izumi Sugo
  • ANTIBODIES WITH MODIFIED ISOELECTRIC POINTS
    Publication number: 20170174757
    Abstract: The invention relates generally to compositions and methods for altering the isoelectric point of an antibody, and in some cases, resulting in improved plasma pharmacokinetics, e.g. increased serum half-life in vivo.
    Type: Application
    Filed: February 27, 2017
    Publication date: June 22, 2017
    Inventors: Gregory Lazar, Bassil I. Dahiyat, Matthew J. Bernett
  • Antibodies with modified isoelectric points
    Patent number: 9605061
    Abstract: The invention relates generally to compositions and methods for altering the isoelectric point of an antibody, and in some cases, resulting in improved plasma pharmacokinetics, e.g. increased serum half-life in vivo.
    Type: Grant
    Filed: January 27, 2014
    Date of Patent: March 28, 2017
    Assignee: Xencor, Inc.
    Inventors: Gregory A. Lazar, Bassil I. Dahiyat, Matthew J. Bernett
  • Anti-glypican-3 antibody
    Patent number: 9102739
    Abstract: An anti-glypican-3 antibody comprising one or more amino acid substitutions introduced in the Fc region is disclosed. Preferably, in the anti-glypican-3 antibody, one or more of the amino acid residues at the positions 239, 298, 326, 330 and 332 in the Fc region are substituted with other amino acid residues. Since the Fc-modified anti-glypican-3 antibody of the invention exhibit enhanced ADCC activity, it is useful in treating cancers, such as hepatic cancer. Also disclosed are an anticancer agent comprising the anti-glypican-3 antibody of the invention and a pharmaceutically acceptable carrier, as well as a method of treating a patient with cancer comprising administering to the patient the anticancer agent of the invention.
    Type: Grant
    Filed: October 11, 2006
    Date of Patent: August 11, 2015
    Assignees: Chugai Seiyaku Kabushiki Kaisha, Xencor, Inc.
    Inventors: Gregory Alan Lazar, Bassil I. Dahiyat, Hisafumi Okabe, Masamichi Sugimoto, Shigeyuki Iijima, Izumi Sugo
  • Anti-Glypican-3 Antibody
    Publication number: 20150098941
    Abstract: An anti-glypican-3 antibody comprising one or more amino acid substitutions introduced in the Fc region is disclosed. Preferably, in the anti-glypican-3 antibody, one or more of the amino acid residues at the positions 239, 298, 326, 330 and 332 in the Fc region are substituted with other amino acid residues. Since the Fc-modified anti-glypican-3 antibody of the invention exhibit enhanced ADCC activity, it is useful in treating cancers, such as hepatic cancer. Also disclosed are an anticancer agent comprising the anti-glypican-3 antibody of the invention and a pharmaceutically acceptable carrier, as well as a method of treating a patient with cancer comprising administering to the patient the anticancer agent of the invention.
    Type: Application
    Filed: October 3, 2014
    Publication date: April 9, 2015
    Applicants: CHUGAI SEIYAKU KABUSHIKI KAISHA, XENCOR, INC.
    Inventors: Gregory Alan Lazar, Bassil I. Dahiyat, Hisafumi Okabe, Masamichi Sugimoto, Shigeyuki Iijima, Izumi Sugo
  • Fc variants with altered binding to FcRn
    Patent number: 8883973
    Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
    Type: Grant
    Filed: February 1, 2010
    Date of Patent: November 11, 2014
    Assignee: Xencor, Inc.
    Inventors: Aaron Keith Chamberlain, Bassil I. Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
  • Fc variants with altered binding to FcRn
    Patent number: 8852586
    Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
    Type: Grant
    Filed: February 1, 2010
    Date of Patent: October 7, 2014
    Assignee: Xencor, Inc.
    Inventors: Aaron Keith Chamberlain, Bassil I. Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
  • ANTIBODIES WITH MODIFIED ISOELECTRIC POINTS
    Publication number: 20140249297
    Abstract: The invention relates generally to compositions and methods for altering the isoelectric point of an antibody, and in some cases, resulting in improved plasma pharmacokinetics, e.g. increased serum half-life in vivo.
    Type: Application
    Filed: January 27, 2014
    Publication date: September 4, 2014
    Applicant: XENCOR, INC.
    Inventors: Gregory A. LAZAR, Bassil I. DAHIYAT, Matthew J. BERNETT
  • Fc variants with altered binding to FcRn
    Patent number: 8802820
    Abstract: The present application relates to optimized IgG immunoglobulin variants, engineering methods for their generation, and their application, particularly for therapeutic purposes.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: August 12, 2014
    Assignee: Xencor, Inc.
    Inventors: Aaron Keith Chamberlain, Bassil I. Dahiyat, John Rudolph Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
  • Antibodies with modified isoelectric points
    Patent number: 8637641
    Abstract: The invention relates generally to compositions and methods for altering the isoelectric point of an antibody, and in some cases, resulting in improved plasma pharmacokinetics, e.g. increased serum half-life in vivo.
    Type: Grant
    Filed: July 29, 2011
    Date of Patent: January 28, 2014
    Assignee: Xencor, Inc.
    Inventors: Bassil I. Dahiyat, Gregory A. Lazar, Matthew J. Bernett
  • Immunoglobulin insertions, deletions, and substitutions
    Patent number: 8399618
    Abstract: An Fc variant of a parent Fc polypeptide, wherein said Fc variant exhibits altered binding to one or more Fc?Rs, wherein said Fc variant comprises at least one amino acid insertion in the Fc region of said parent Fc polypeptide.
    Type: Grant
    Filed: December 23, 2011
    Date of Patent: March 19, 2013
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Bassil I. Dahiyat, Wei Dang, Sher Bahadur Karki, Omid Vafa
  • Fc variants with altered binding to FcRn
    Patent number: 8394925
    Abstract: The present application relates to a variant Fc region comprising the double mutation 428L/434S that increases serum half-life and the numbering is according to the EU index.
    Type: Grant
    Filed: December 15, 2011
    Date of Patent: March 12, 2013
    Assignee: Xencor, Inc.
    Inventors: Aaron Keith Chamberlain, Bassil I. Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
  • Fc variants with altered binding to FcRn
    Patent number: 8367805
    Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
    Type: Grant
    Filed: December 22, 2008
    Date of Patent: February 5, 2013
    Assignee: Xencor, Inc.
    Inventors: Aaron Keith Chamberlain, Bassil I. Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
  • FC variants with altered binding to FCRN
    Patent number: 8338574
    Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
    Type: Grant
    Filed: February 1, 2010
    Date of Patent: December 25, 2012
    Assignee: Xencor, Inc.
    Inventors: Aaron Keith Chamberlain, Bassil I. Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
  • Fc variants with altered binding to FcRn
    Patent number: 8324351
    Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
    Type: Grant
    Filed: February 1, 2010
    Date of Patent: December 4, 2012
    Assignee: Xencor, Inc.
    Inventors: Aaron Keith Chamberlain, Bassil I. Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
  • Fc variants with altered binding to FcRn
    Patent number: 8318907
    Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
    Type: Grant
    Filed: February 1, 2010
    Date of Patent: November 27, 2012
    Assignee: Xencor, Inc.
    Inventors: Aaron Keith Chamberlain, Bassil I. Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
  • Optimized Fc Variants
    Publication number: 20120258092
    Abstract: The present invention relates to optimized CD20 antibodies having Fc variants, methods for their generation, and method for their application, such as methods of enhancing macrophage activation, particularly for therapeutic purposes.
    Type: Application
    Filed: December 23, 2011
    Publication date: October 11, 2012
    Applicant: Xencor, Inc.
    Inventors: Bassil I. Dahiyat, Gregory A. Lazar, Omid Vafa
  • NOVEL IMMUNOGLOBULIN INSERTIONS, DELETIONS, AND SUBSTITUTIONS
    Publication number: 20120225058
    Abstract: An Fc variant of a parent Fc polypeptide, wherein said Fc variant exhibits altered binding to one or more Fc?Rs, wherein said Fc variant comprises at least one amino acid insertion in the Fc region of said parent Fc polypeptide.
    Type: Application
    Filed: December 23, 2011
    Publication date: September 6, 2012
    Applicant: Xencor, Inc.
    Inventors: Gregory A. Lazar, Bassil I. Dahiyat, Wei Dang, Sher Bahadur Karki, Omid Vafa
  • Fc VARIANTS WITH ALTERED BINDING TO FcRn
    Publication number: 20120088905
    Abstract: The present application relates to a variant Fc region comprising the double mutation 428L/434S that increases serum half-life and the numbering is according to the EU index.
    Type: Application
    Filed: December 15, 2011
    Publication date: April 12, 2012
    Applicant: XENCOR, INC.
    Inventors: AARON KEITH CHAMBERLAIN, BASSIL I. DAHIYAT, JOHN R. DESJARLAIS, SHER BAHADUR KARKI, GREGORY ALAN LAZAR
  • ANTIBODIES WITH MODIFIED ISOELECTRIC POINTS
    Publication number: 20120028304
    Abstract: The invention relates generally to compositions and methods for altering the isoelectric point of an antibody, and in some cases, resulting in improved plasma pharmacokinetics, e.g. increased serum half-life in vivo.
    Type: Application
    Filed: July 29, 2011
    Publication date: February 2, 2012
    Applicant: XENCOR, INC.
    Inventors: Bassil I. Dahiyat, Gregory A. Lazar, Matthew J. Bernett